About vinorelbine di tartarate equivalent to vinorelbine
Vinca alkaloid chemotherapy medicine
Used for
- Treats non-small cell lung cancer, often with other medicines.
- Treats advanced breast cancer, alone or with other medicines.
Usual adult dose
By intravenous infusion, commonly 25–30 mg/m² once weekly; schedules depend on cancer and combination treatment.
Common side effects
- Low white blood cell counts and increased infection risk
- Constipation, nausea, vomiting, or diarrhoea
- Anaemia or low platelets
- Hair loss, fatigue, or injection-site irritation
Important warnings
- For intravenous use only; injection outside the vein can cause serious tissue damage.
- Can severely suppress blood counts; regular blood tests are needed.
- May cause nerve problems, including tingling, weakness, or constipation.
- Avoid live vaccines; infection risk may be serious.
Pregnancy
May harm an unborn baby. Pregnancy should be avoided during treatment; discuss reliable contraception with the cancer-care team.
Breastfeeding
Breastfeeding is not recommended during treatment.
Interactions
- Other medicines that suppress bone marrow can increase blood-count problems.
- Strong CYP3A inhibitors or inducers may change vinorelbine levels.
- Mitomycin can increase the risk of lung toxicity.
- Live vaccines may cause serious infection.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.